ARRY-382 / Pfizer, BMS - LARVOL DELTA

In silico targeting of colony-stimulating factor-1 receptor: delineating immunotherapy in cancer. (PubMed, Explor Target Antitumor Ther) - "The 3D conformers of edicotinib, DCC-3014, ARRY-382, BLZ-945, chiauranib, dovitinib, and sorafenib were obtained from PubChem Database. Pyrimidines are potent inhibitors that interact with CSF1R residues. DCC-3014 and ARRY-382 exhibit exceptional pharmaceutical potential exhibiting great structural stability and affinity."

IO biomarker • Journal • Oncology • CSF1R

A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1b/2 | N=82 | Terminated | Sponsor: Pfizer | Completed ➔ Terminated; Study was halted prematurely due to insufficient efficacy. Not due to safety reasons.

Combination therapy • IO biomarker • Trial termination • Breast Cancer • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • ALK • EGFR

ARRY-382 in Combination with Pembrolizumab in Patients With Advanced Solid Tumors: Results From a Phase 1b/2 Study. (PubMed, Clin Cancer Res) - P1b/2 | "Although limited clinical benefit was observed, ARRY-382 plus pembrolizumab was well tolerated."

Combination therapy • Journal • P1/2 data • Oncology • Ovarian Cancer • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1b/2; N=82; Completed; Sponsor: Pfizer; Phase classification: P1/2 ➔ P1b/2

Clinical • Combination therapy • Phase classification • Breast Cancer • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer